Tips for Collecting a High-quality FNA Sample
Number of FNA Passes
For cytology collection, it is recommended to perform at least two needle passes, with up to five passes when appropriate. Each needle pass should be brief, typically lasting only 5 to 10 seconds. Once a flash of blood appears in the needle hub, stop.
For Interpace testing, only one dedicated pass is required.
Selecting the Appropriate FNA Pass to Use for Molecular Testing
Place the entire second needle pass into the provided molecular collection vial.
After cytology preparation, additional passes from the same nodule may be rinsed into the vial. For each rinse, expel the material from the syringe into the vial, then draw a small amount of vial fluid into the needle and expel it back into the vial to clear any remaining material from the needle hub.
If CytoLyt® is used for cytology, do not rinse any needle into the molecular vial if it has come into contact with CytoLyt.
Needle Size
For most cases, a 25- or 27-gauge needle is appropriate for obtaining an adequate sample.1 Larger needles may increase the amount of blood in the sample, which can affect specimen quality. A new needle should be used for each pass into the nodule.
Ultrasound and Numbing Gel Considerations
If ultrasound or numbing gels are used, ensure the needle insertion area is thoroughly cleaned before inserting the needle into the nodule. Gel contamination may impact the quality of the sample and obscure cytomorphology.3
Alcohol wipes can be used as an alternative to gels for short FNA procedures. Because alcohol acts as a conductive agent, this approach can help reduce the risk of gel contamination.
Air in Syringe
Excess air in the syringe can make the specimen collection process more difficult. If the collection vial bubbles over, there is likely too much air in the syringe.
Typically, only 2 to 3 cc of air in a 10 mL syringe is needed to express the cells into the collection vial or onto a glass slide.
Small Steps Can Make a Big Difference
From needle selection to specimen preparation, small steps throughout the collection and handling process can influence specimen quality. Focusing on proper collection techniques can help ensure that adequate specimen samples are submitted for thyroid molecular testing.
For additional information on thyroid FNA specimen collection, please find quick reference guides and videos below.
FNA Collection and Specimen Preparation Videos
We thank PathNet, one of our cytopathology partners, for sharing these educational videos on thyroid FNA collection and specimen preparation.
Book Method Procedure
Liquid Based Collection Procedure
Diff-Quik Stain Procedure
About Mark A. Lupo, MD, ECNU
Dr. Lupo is the founder and medical director of the Thyroid & Endocrine Center of Florida located in Sarasota. He is board certified in Endocrinology and Internal Medicine. His endocrine practice is limited to thyroidology with an emphasis on structural thyroid disease – nodules and cancer, as well as autoimmune thyroid disease. He has been very involved in teaching other physicians neck sonography, ultrasound-guided biopsy techniques, and thyroid nodule/cancer management. He is also an active member of the American Thyroid Association, Endocrine Society, American Institute of Ultrasound in Medicine, and Mensa.
These tips reflect the clinical experience and professional opinions of Dr. Lupo.
Patient management decisions are based on the independent medical judgment of the physician and molecular test results should be taken into consideration in conjunction with all relevant imaging, clinical findings, patient and family history, as well as patient preference.
References: 1. American Thyroid Association. Quality Assurance in Cytopathology and Histopathology of the Thyroid. American Thyroid Association. Accessed August 21, 2026. https://www.thyroid.org/professionals/laboratory-services-library/quality-assurance-cytopathology. 2. Haugen BR, et al. Thyroid. 2016;26(1):1-133. 3. CIVCO Medical Solutions. Improve Fine Needle Aspiration (FNA) Biopsies by Eliminated a Common Step. CIVCO Medical Solutions. Accessed August 26, 2026. https://www.civco.com/in-the-know/improve-fine-needle-aspiration-biopsies. 4. Interpace Diagnostics. Directory of Services. 5. Ali SZ, et al. Thyroid. 2023;33(9):1039-1044. doi:10.1089/thy.2023.0141. 6. Finkelstein SD, et al. Thyroid. 2022;32(11):1362-1371. 7. Hsiao SJ and Nikiforov YE. Molecular Advances in the Diagnosis and Treatment of
Thyroid Cancer. Ento Key. June 1, 2020. Accessed October 23, 2023.
FAQs
What are common reasons a sample might be rejected for molecular testing, and how can they be avoided?
Samples may be rejected due to improper specimen collection, labeling issues, use of expired collection kit materials, specimen age, or slide quality problems. In addition, all sample shipments must include a copy of the corresponding cytopathology report. Following specimen handling requirements and slide preparation guidelines can help minimize delays and reduce the likelihood of sample rejection.
What sample types are required for ThyGeNEXT + ThyraMIRv2 testing?
The specimen types accepted for ThyGeNEXT + ThyraMIRv2 testing include:4
- 1 dedicated FNA pass collected within the provided collection buffer. The specimen is stable for up to 6 weeks at room temperature when placed in the provided collection vial.
- The second FNA pass is preferred. For larger nodules, the needle from additional passes may be rinsed into the buffer to help with heterogeneity of nodules.
- 1 diagnostic cytology slide with at least 80-100 follicular cells
- Accepted stains: Diff-Quik®, Giemsa, or PAP (Diff-Quik is preferred)
- FFPE tissue/cell block or 1 H&E and 8 unstained recuts
- Presurgical specimens only, up to 6 months from collection
Interpace captures a high-resolution, full-color digital image of all cases, which is retained for future reference per CAP Guidelines. This can help minimize the need for repeat FNAs and provide convenience for both physicians and patients.
What categories of thyroid nodules can be evaluated with molecular testing?
Molecular testing is useful when a fine-needle aspiration biopsy is inconclusive or indeterminate.5 The current Bethesda Guidelines recommend molecular testing for samples classified by cytology as Atypia of Undetermined Significance (Bethesda III) and Follicular Neoplasm/Hürthle Cell Neoplasm (Bethesda IV).5 The guidelines also recognize molecular testing as part of the management of Suspicious for Malignancy (Bethesda V) nodules.5
ThyGeNEXT + ThyraMIRv2 can further stratify the risk of malignancy in indeterminate thyroid nodules and help inform clinical management.6